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Abstract
Hormonal therapy is a major and effective tool in the treatment of prostate cancer patients.
This is especially true for patients in the advanced stages of disease. Unfortunately, almost
all prostate cancer cells will develop into castration‐resistant prostate cancer (CRPC)
despite continued therapy and suppression of testosterone levels. Up until 5–6 years ago,
there was little effective therapy for the treatment of CRPC patients. However, recently,
a variety of methodologies and drugs such as cabazitaxel and sipuleucel‐T have been
approved globally for the treatment of CRPC. Two novel drugs, abiraterone acetate and
enzartamide, have also become available as potential treatment options. However, the
anticancer effects of these two drugs are not always satisfactory in terms of prolonging
survival. These drugs are also associated with adverse events and are expensive when
compared with the costs of previously used anticancer drugs. In this section, we pay
particular attention to hormonal therapies that do not include the use of abiraterone acetate
or enzartamide. We believe that a detailed understanding of the range of currently available
hormonal therapies, including their associated benefits and limitations, is important for
supporting the prolongation of survival in patients with advanced prostate cancer.
Therefore, this section offers a valuable discussion on the treatment strategies for prostate
cancer including CRPC.
Keywords: steroidal antiandrogens, nonsteroidal anti‐androgens, estrogens, steroids,
castration‐resistant prostate cancer
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1. Introduction
Prostate cancer is one of the most common malignancies diagnosed worldwide in men. At
present, prostate cancer patients with organ‐confined disease can obtain an excellent oncolog‐
ical outcome through radical operation and radiotherapy. On the other hand, a variety of
hormonal therapies are often necessitated for patients with advanced prostate cancer. Be‐
cause the malignant aggressiveness of prostate cancer has been known to be suppressed by
orchiectomy  since  the  1940s,  androgen  deprivation  therapy  (ADT)  has  been  commonly
administered. This is associated with the fact that the prostate is an androgen‐dependent organ
and that androgen receptor (AR) signaling plays an important role in the growth and progres‐
sion of prostate cancer cells. In fact, as a first‐line therapy, surgical castration, chemical castration,
and anti‐androgen treatment are usually used in the treatment of patients with metastatic
prostate cancer [1]. Anti‐androgens are broadly divided into two chemical types, steroidal and
nonsteroidal. As a part of hormone therapy, estrogen and estrogen‐containing agents can also
be administered to patients with prostate cancer. A variety of glucocorticoids is also common‐
ly used.
However, most hormone‐naive prostate cancer patients will develop castration‐resistant
prostate cancer (CRPC) despite therapeutic suppression of testosterone levels and even though
continued therapy can proceed without adverse effects. Furthermore, CRPC has a high
malignant potential and aggressiveness. This is due to the number of heterogeneous types of
cancer cells that develop a variety of abnormal signal pathways as a means to survive in the
castration environment. In fact, the prognosis of patients with CRPC is often poor and no
therapy that had high efficacy and high compliance had been available until the middle of the
2000s. In 2004, two clinical trials with large study populations and sophisticated methodologies
demonstrated that the anticancer effects of docetaxel‐based chemotherapy are superior to
those of mitoxantrone and prednisolone treatments [2, 3]. Based on these facts, docetaxel has
become a standard therapy for the treatment of CRPC. However, prolongation of survival by
docetaxel chemotherapy is less than six months [4]. Additionally, docetaxel has major
problems related to multiple and severe adverse events [3, 5]. Consequently, many urologists,
physicians, and investigators have focused on the development of new therapeutic strategies
to prolong survival in CRPC patients.
During the past 5–6 years, a variety of treatment methods and drugs for CRPC have been
approved in many countries. Approved drugs include cabazitaxel and sipuleucel‐T [6, 7]. In
addition, ADT options for patients with CRPC have also changed during the past few years
as the novel drugs, abiraterone acetate and enzartamide (termed as next‐generation anti‐
androgens) have become available [8, 9]. Abiraterone is a specific steroidogenic inhibitor that
irreversibly inhibits CYP17A1 [10]. Enzalutamide is an anti‐androgen‐receptor inhibitor that
has been shown to improve prognosis in patients with CRPC [11]. Thus, many urologists and
medical oncologists agree that treatment strategies for patients with CRPC are developing
remarkably well [12]. However, the anticancer effects, including prolongation of patient
survival, associated with these new treatments are not always adequate. For example, CRPC
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develops resistance to these second‐generation agents quickly and thus the anticancer effects
of abiraterone acetate and enzartamide can be decreased [13, 14].
Thus, although a variety of new anticancer agents have been developed, their anticancer effects
in CRPC patients are not always satisfactory, particularly in terms of prolonging patient
survival. In addition, CRPC patients often have many comorbidities due to past treatments
and aging. Therefore, in discussions on treatment strategies for prostate cancer patients, it is
essential to assess information regarding drug adverse reactions and safety. In addition, special
attention must be paid to the cost of therapies as treatment periods are usually lengthy, and
recently developed anticancer agents, including next‐generation anti‐androgens, are expen‐
sive. Based on these facts, we present in this chapter, the clinical benefits, safety, and caution
points of hormonal therapies that do not involve next‐generation antiandrogens. In other
words, we will re‐evaluate hormonal therapy for treatment of prostate cancer patients in the
era of next‐generation antiandrogen agents.
2. Antiandrogen agents
As mentioned earlier, prostate cancer cells are, in the majority of cases, androgen‐dependent.
Testosterone, of testicular origin, comprises 95% of androgen content. Androgens stimulate
cell proliferation and tumor growth by binding to AR in the cancer cells. Therefore, the first‐
line of treatment for advanced prostate cancer has been androgen deprivation by medical
castration through administration of luteinizing hormone‐releasing hormone agonist/antag‐
onists or by surgical castration with bilateral orchiectomy. Antiandrogens are AR receptor
antagonists that compete with dihydroteststerone for AR binding. Upon binding, the antian‐
drogens act to inhibit the tumor growth in patients with prostate cancer. This section reviews
first‐generation antiandrogens used in the treatment of prostate cancer including CRPC.
2.1. Steroidal antiandrogens
Antiandrogens can be classified based on their chemical structure into two types, steroidal and
nonsteroidal. The steroidal antiandrogens, cyproterone acetate, spironolactone, synthetic
progestins, and chlormadinone acetate are well known in oncology. We first discuss the
steroidal antiandrogens, progesterone analogue mifepristone (RU‐486), cyproterone acetate,
and the mineralocorticoid analogue, spironolactone. However, it should be noted that these
agents are rarely used in clinical situations because of their partial androgenic agonistic–
antagonistic activity.
RU‐486 is a progesterone analogue best known as a progesterone receptor (PR) antagonist. It
was developed in France as a medical approach to terminating pregnancy [15]. RU‐486 also
inhibits glucocorticoid receptor (GR) function and has been used for treating Cushing syn‐
drome [16]. More importantly, RU‐486 is also an AR antagonist. Binding studies indicate that
it has a higher affinity for AR than either hydroxyflutamide or bicalutamide [17]. However, a
Phase II study of RU‐486 demonstrated limited activity in patients with CRPC. In that study,
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RU‐486 also stimulated a marked increase in the levels of adrenal androgens, testosterone, and
dihydrotestosterone (DHT) [18].
Cyproterone acetate is nonspecific and can activate the mineralocorticoid receptor (MR), GR,
and PR. A meta‐analysis of randomized trials showed that combined androgen blockade
(CAB) with nonsteroidal antiandrogens, including nilutamide and flutamide, appeared
slightly favorable to cancer patient survival when compared with the effects of androgen
suppression (AS) monotherapy. On the other hand, CAB with cyproterone acetate was
associated with an inferior survival rate [19].
Spironolactone is an MR antagonist that is used to treat side effects related to mineralocorticoid
excess. Richards et al. [20] showed that spironolactone significantly activates both wild type
and mutant AR and that it should be avoided in the treatment of all patients with CRPC. As a
result, CAB with steroidal antiandrogens has been recognized as an inferior treatment to the
use of nonsteroidal antiandrogens and is considered unsuitable for prostate cancer treatment.
2.1.1. Steroidal antiandrogens in Japan
Cyproterone acetate, RU‐486, and nilutamide are not approved in Japan for use in the treatment
of patients with prostate cancer. On the other hand, chlormadinone acetate is approved in
Japan but is not used in other countries. Evaluation of the relative efficacy and safety of these
agents globally is therefore difficult. However, chlormadinone acetate has been reported to
have advantages in terms of causing fewer adverse events. We therefore present information
regarding chlormadinone acetate in this section.
Several Japanese groups have reported on the efficacy of chlormadinone acetate as an alter‐
native antiandrogen therapy in the treatment of men with relapsed prostate cancer following
first‐ or second‐line hormonal therapy [21–23]. Steroidal antiandrogens including cyproterone
acetate and chlormadinone acetate have also proven efficacious in the treatment of prostate
cancer patients who suffer from hot flushes [24, 25]. However, Igawa et al. [26] reported that
CAB therapy using chlormadinone acetate led to a significantly poorer survival outcome
versus the use of bicalutamide. Nevertheless, because this survival trend was not observed in
M0 cases, they concluded that chlormadinone acetate might still be an option for CAB therapy,
depending on the clinical stage and the severity of adverse effects including hot flushes [26].
2.1.2. Clinical study and basic research
Ongoing clinical studies and basic research using chlormadinone are presented in Table 1.
There has been at least one evaluation on whether low‐dose chlormadinone has an effect on
continued active surveillance (Table 1, No.1; UMIN000012284). Another study has evaluated
whether chlormadinone has a more favorable effect on lipid and bone metabolism than that
of bicalutamide (No.2; UMIN000018478). In terms of basic research, Koike et al. [27] have
reported on the effects of chlormadinone acetate on the development and progression of
prostate cancer in their PTEN‐deficient mouse model (Table 1, No. 3). They demonstrated that
chlormadinone acetate treatment suppressed the proliferation of cancer cells but did not
decrease the development of prostatic intraepithelial neoplasia (PIN). This means that
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chlormadinone did not act to prevent prostate cancer onset. The findings from this study
suggest that inhibiting androgen signaling is effective in preventing the proliferation of
prostate cancer caused by PTEN dysfunction. It has also been suggested that androgen plays
an important role at the early stages of prostate cancer development in this mouse model [27].
Clinical study
No Concept and outline Objectives
1 Multicenter, randomized, double
blind, placebo‐controlled parallel
group comparative study to
evaluate the effect of low‐dose
chlormadinone acetate on the
rate of continued active
surveillance of patients with low‐
risk prostate cancer
To evaluate the effect of
chlormadinone acetate on the rate
of continued active surveillance by
administration of low‐dose
chlormadinone acetate or placebo
to patients with low‐risk prostate
cancer
2 Impact of endocrine therapy on
lipid metabolism and bone





To investigate the effect of
chlormadinone acetate and GnRH
agonist combination therapy or
bicalutamide and GnRH agonist
combination therapy for prostate
cancer men on lipid metabolism
and bone metabolism
Basic research
3 Conditional PTEN‐deficient Mice
as a Prostate Cancer
Chemoprevention Model [27]
The potential of PTEN‐deficient
mice was examined by evaluating
the chemopreventive efficacy of
the anti‐androgen, chlormadinone
acetate
Table 1. Clinical studies and basic research on chlorm.
2.2. Nonsteroidal antiandrogens
The nonsteroidal antiandrogens, flutamide and bicalutamide, are well known in oncology and
are major therapeutic tools in the treatment of prostate cancer patients. Therefore, information
on their anticancer effects, including causation of decreases in serum prostate‐specific antigen
(PSA) levels and enhanced survival rates, has been presented in numerous reviews. There is
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also a corresponding amount of literature on their adverse effects. Here, we introduce the
clinical benefits and limitations of nonsteroidal antiandrogens in the treatment of CRPC
patients.
2.2.1. Optional treatment for castration‐resistant prostate cancer
Bicalutamide is the most common used steroidal antiandrogen due to its good curative effects
and limited adverse effects. It is combined with luteinizing hormone‐releasing hormone
agonist/antagonist therapy to treat CRPC. Some researchers have indicated that dose elevation
of antiandrogen agents may enhance their efficacy. For example, the routine dose of bicaluta‐
mide is 50 mg/day but evidence suggests that higher doses might be more effective [28]. Klotz
et al. [29] reported that 22% of the patients showed a ≥50% decline in serum PSA levels
following an increase in the dose of bicalutamide from 50 mg/day to 150 mg/day. Lodde et al.
[30] reported the palliative benefits of 150 mg/day bicalutamide therapy in 44.7% of 38 CRPC
nonmetastasis patients. These studies therefore demonstrate that a high proportion of CRPC
patients could benefit from treatments involving elevated doses of steroidal antiandrogens.
Available data also indicate that bicalutamide at a dose of much greater than 50 mg (at least
150 mg) daily in combination with castration may increase efficacy against CRPC progression.
However, in all these studies earlier, either the median response duration is brief or the
evaluation indices are limited.
Meanwhile, potential predictive factors for improved responses to high‐dose (150 mg)
bicalutamide therapy have been discussed. Qian et al. [28] suggested that secondary hormonal
therapy with 150 mg bicalutamide daily was effective in patients with CRPC. Patients with a
lower Gleason score, lower serum PSA concentrations, and who were using flutamide as a
first‐line nonsteroidal antiandrogen achieved more benefits when treated with bicalutamide
150 mg therapy. Patients with PSA decreases ≥85% had improved times of response to
bicalutamide 150 mg therapy. Moreover, when compared with the common side effects of
androgen‐deprivation therapy, the adverse effects of bicalutamide 150 mg therapy were well‐
tolerated.
2.2.2. Combination with molecular target drugs
Angiogenesis, mediated by the vascular endothelial growth factor receptor (VEGFR) pathway,
may be a good target for treatment of prostate cancer; it has been implicated in both the
development and progression of the disease [31–33]. Studies have found that median levels of
plasma VEGF are significantly higher in patients with metastatic prostate cancer when
compared with those with localized cancer and that elevated plasma and urine levels of VEGF
may be independent negative prognostic factors [34–36]. These findings suggest that inhibiting
the VEGFR pathway might be an effective approach in prostate cancer.
In addition, the mammalian target‐of‐rapamycin (mTOR) is a critical molecule in controlling
the proliferation of tumor cells. It can be activated by mutation or activation of signaling
molecules such as PI3K or Akt. Alterations in the PI3K/Akt/mTOR pathway play an important
role in prostate cancer, and it is estimated that upregulation occurs in 30–50% of prostate cancer
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cases [37]. Recently, clinical trials on the efficacy and tolerability of antiandrogen and molec‐
ular target combination therapy have been conducted (Table 2), but these have included only
a small number of patients. Results have shown that neither the PSA‐response rate nor the
PSA‐progression free survival is fully satisfactory. In addition, peculiar adverse events have
been associated with molecular target agents. Hence, these therapies are not currently in
practical use.
Year Molecular target therapy N Phase PSA‐RR PSA‐PFS Ref
2012 Everolimus: 10 mg 36 II 5.6% 8.7 wks. [33]
2012 Sorafenib: 400 mg 39 II [38]
2013 Ridaforolimus: 30 mg 12 — 36% — [39]
2014 Vandetanib: 300 mg 19 II 18% 3.16 mos. [40]
2015 Pazopanib: 800 mg 13 II 17% — [41]
N, number of patients; PSA, prostate specific antigen; RR, response rates; Ref, references; wks, weeks; mos, months.
*PSA response was defined as ≥ 50% decline.
**PSA response was defined as ≥ 30% decline.
Table 2. Combination therapy of bicalutamide and molecular target therapy for castration‐resistant prostate cancer.
3. Estrogens and estrogen‐based therapy
It is well‐known that estrogens carry a significant risk for cardiovascular events. Androgen
deprivation therapy is therefore the first choice as primary therapy for advanced prostate
cancer. However, many authors have now investigated the anticancer effects of diethylstil‐
bestrol [42], transdermal estradiol [43], and more recently, oral ethinylestradiol [44, 45] in the
treatment of CRPC as well as in the treatment of hormone‐naive prostate cancer. These authors
have concluded that estrogen therapy is still relevant and can induce PSA response (50% PSA
decline) rates as high as 69.6% in CRPC patients. Moreover, estrogen therapy is associated with
fewer of the toxicities associated with ADT. It can maintain bone mineral density, suppress
hot flushes, and improve cognitive function and lipo‐metabolism in castrated men.
Estrogens inhibit the hypothalamic–pituitary–testicular axis through negative feedback
mechanisms. Moreover, estrogen administration can induce a decrease in the levels of adrenal
androgens and testosterone produced by the Leydig cells of the testes [46]. A direct cytotoxic
effect of estrogens on prostate cancer cells has not been fully investigated. However, there are
some reports on their cytotoxic effects on in vivo and in vitro castrate xenograft models [47, 48].
3.1. Diethylstilbestrol
Diethylstilbestrol (DES) is a synthetic estrogen. In the 1940s, Huggins and Hodges [49] re‐
ported that DES suppressed the progression of prostate cancer. DES was then used as a first‐
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line hormonal therapy for over 10 years in the treatment of prostate cancer patients.
However, in 1970, increased mortality from cardiovascular and thromboembolic events as‐
sociated with DES was reported in a prospective randomized controlled trial (VACURG
study) [50]. Briefly, of the 1103 patients treated with DES (5 mg/daily) with no anticoagula‐
tion therapy, 17% of the patients died due to cardiovascular events (the mortality associated
with cardiovascular event in the placebo group was 11.7%). Therefore, to suppress the risk
of adverse events including cardiovascular disease, administration of lower doses of DES
was investigated in clinical trials. However, although this approach significantly reduced
cardiovascular morbidity, it was still higher than that associated with castration. For exam‐
ple, in the EORTC 30805 study, the cardiovascular mortality of the DES (1 mg/daily) and or‐
chidectomy‐alone groups was 14.8% and 8.3%, respectively [51]. Meanwhile, the
cardiovascular toxicity of DES was significantly decreased by the use of anticoagulants such
as warfarin or aspirin [52, 53]. From these facts, we note that DES treatment has a relatively
high risk of cardiovascular events and that it must be used with anticoagulation therapy. On
the other hand, we also understand that DES is one of the most effective and useful thera‐
peutic options for prostate cancer patients as it can suppress cancer progression.
In terms of PSA response (>50% decline from baseline) to DES treatment in CRPC patients,
approximately 40% patients were reported to be PSA responders [42, 54]. More recently,
Wilkins et al. [55] disclosed results from a larger CRPC cohort (231 patients) treated with DES
at a dose of 1–3 mg daily and with aspirin at 75 mg. They reported that the PSA response rate
was 28.9% and that the median time to PSA progression was 4.6 months. These results cannot
be considered satisfactory in terms of cancer control. However, interestingly, Wilkins et al. also
reported that 18% of the patients showed an improvement in bone pain. Other investigators
have also observed an improvement in certain types of pain in CRPC patients treated with
DES [56]. Overall, DES remains a reasonable palliative option for patients with symptomatic
CRPC even though its survival benefits may be limited. However, careful informed consent
from the patients who are fully apprised of the cardiovascular risks associated with DES should
be required.
3.2. Transdermal estradiol
As mentioned earlier, cardiovascular disease and thrombosis are the most dangerous adverse
events associated with estrogen‐based agents. In contrast to oral estrogens, parenterally
administered estrogens do not increase liver protein synthesis and may be less prothrombotic
[43]. In fact, in women who receive estrogen replacement therapy, the risk of cardiovascular
events is increased with oral, but not transdermal, estradiol. There have been several infor‐
mative studies about safety, potential side effects, and efficacy in the use of transdermal
estradiol in the treatment of CRPC patients [43, 57]. In a Phase II study, CRPC patients suffering
continued disease progression after primary hormonal therapy were treated with transdermal
estradiol (0.6 mg per 24 h) [43]. Toxicity associated with the transdermal estradiol application
was modest and no cardiovascular events occurred. In terms of cancer control, three of the 24
patients (12.5%) showed a PSA response. Another study analyzed the safety and efficacy of
transdermal estradiol patch in the treatment of CRPC patients after ADT and chemotherapy
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[57]. This study showed a PSA response rate of 10%. No cardiovascular events were observed.
Thus, transdermal estrogen therapy was well‐tolerated in the CRPC patients, and there were
no significant cardiovascular complications. However, as with oral estradiol, the anticancer
effects of transdermal estradiol appear to offer very limited survival benefit.
3.3. Ethinylestradiol
Treatment with ethinylestradiol was used in the 1980s as palliative therapy in patients with
advanced prostate cancer. However, ethinylestradiol treatment has become less common since
the development of newer treatment forms such as ADT [58]. On the other hand, one advantage
of ethinylestradiol is that it is inexpensive. This is an important consideration in assessing
treatment strategies. At present, ethinylestradiol is not used as a first‐line hormonal therapy.
However, it is still used as a second‐line or a later option for CRPC patients [59]. Several
investigators have reported on the efficacy and adverse events of ethinylestradiol in treatments
of CRPC patients. For example, Onita et al. [60] reported that a decrease in serum PSA levels
was seen in all 15 tested CRPC; 11 patients (73.3%) showed decreases of more than 50% without
severe side effects. Other investigators have performed ethinylestradiol monotherapy at a dose
of 1.5 mg/day for CRPC patients for whom more than one salvage therapy had not been
effective [45]. In this retrospective study, the PSA response rate was 69.6%, and the median
progression‐free survival was estimated as 300 days. On the other hand, adverse events
occurred in 3 of the 23 patients (13%). These adverse effects included elevation of liver
enzymes, anorexia, and heart failure. Recently, results of a larger prospective study of
ethinylestradiol monotherapy were reported [44]. In this study, 116 patients with metastatic
CRPC were administered ethinylestradiol at a daily dose of 1 mg and with aspirin at a daily
dose of 100 mg. A PSA response was observed in 79 patients (70.5%). PSA levels lower than 4
ng/mL in serum were observed in 24 patients (21.4%). Toxic adverse effects that required
Year N Daily dose (mg) PSA‐RR (%) PSA‐PFS Ref
Diethylstilbestrol 1998 21 1.0 42.9 — [42]
Diethylstilbestrol 2000 34 1.0 NA 6 mos. [54]
Diethylstilbestrol 2012 243 1.0–3.0 28.9 137 days [55]
Trans. estradiol 2005 24 0.6 12.5 12 wks. [56]
Trans. estradiol 2012 20 0.4 10.0 — [57]
Ethinylestradiol 2003 10 1.0 90.0 12.0 mos [59]
Ethinylestradiol 2009 18 1.0–3.0 73.3 15.0 mos [60]
Ethinylestradiol 2010 24 1.5 69.6 300 days [45]
Ethinylestradiol 2015 116 1.0 70.5 15.1 mos [44]
N, number of patients; PSA, prostate specific antigen; RR, response rates; PFS, progression‐free survival; Ref, references;
mos, months; NA, not available; wks., weeks; Trans, transdermal.
*PSA response was defined as ≥50% decline.
Table 3. Summary of the anticancer effects in the studies of estrogens.
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treatment cessation were described for 26 patients (23.2%). The main adverse effect requiring
treatment cessation was thromboembolism (18 patients). Overall, however, no patient died as
a result of treatment toxicity.
In addition to monotherapy, several clinical studies on combination therapies that include
ethinylestradiol have been conducted. For example, in one small study, administration of 1
mg oral ethinylestradiol combined with lanreotide acetate (somatostatin analog) resulted in a
decline in serum PSA levels of >50% in 9 out of the 10 CRPC patients (90%) [59]. Overall,
administration of ethinylestradiol in CRPC cases resulted in a high percentage of PSA
responses. The potential for cardiovascular toxicity could be managed through appropriate
patient selection and concomitant anticoagulation therapy. A summary of the anticancer
effects of estrogens is shown in Table 3.
4. Corticosteroids
Corticosteroids suppress the production of androgens from the adrenal gland through the
regulation of the pituitary–adrenal axis. Consequently, corticosteroids can inhibit the malig‐
nant behavior and survival of prostate cancer cells. In addition to this indirect role, they are
known to inhibit the growth of prostate cancer cells by interfering directly with a variety of
cancer‐related factors [61]. Recognizing this, corticosteroids have been used in cancer therapy
for decades. They have been administered to prostate cancer patients both as a mono‐therapy
and in combination with other anticancer agents. Unfortunately, its anticancer effects,
including prolongation of survival, are limited when used as a single agent [62]. In this section,
we discuss corticosteroids in terms of their efficacy when used in combination therapy for the
treatment of CRPC.
4.1. Which types of glucocorticoids are better?
A variety of glucocorticoids, including prednisone, prednisolone, hydrocortisone, and dexa‐
methasone, have anticancer effects and associated clinical benefits for prostate cancer pa‐
tients [63–65]. However, many investigators have suggested that their anticancer effects
differ from each other. For example, the PSA response rates of prednisolone (5 mg × 2 =10
mg daily) and hydrocortisone (40 mg daily) administered to CRPC patients were reported to
be 26% and 22%, respectively [66, 67]. In the case of prednisone, 34% of the patients had a
decrease in PSA levels of more than 50% [64]. In the previous reports, PSA response rates
associated with prednisone, prednisolone, and hydrocortisone treatments have ranged from
9 to 33% [68]. On the other hand, in the case of dexamethasone, decreases in PSA levels of
≥50% were detected in 50 of 102 (49%) of the CRPC patients treated at a dose of 0.5 mg daily
[68]. Other investigators also reported a similar decrease in PSA levels in 61% of CRPC pa‐
tients treated with dexamethasone at a dose of 1.5 mg or 2.25 mg daily [69]. Based on these
reports, dexamethasone appears to have a significantly greater anticancer effect than other
glucocorticoids [70]. However, one report indicated that dexamethasone at a dose of 1.5 mg
daily showed a reduction of PSA levels of ≥50% in only 28% of the CRPC patients [70]. Thus,
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there is no general agreement on what specific glucocorticoid should be recommended for
the treatment of CRPC patients. Recently, the first head‐to‐head clinical comparison of pre‐
dnisolone versus dexamethasone as monotherapies in the treatment of CRPC patients was
conducted [68]. In this study, patients were randomized, in a 1:1:1 ratio, between adminis‐
tration of intermittent dexamethasone (8 mg twice daily for 3 days every 3 weeks), daily
dexamethasone (0.5 mg once daily), and prednisolone (5 mg twice daily). The intermittent
dexamethasone treatment was terminated mid‐study due to a lack of observed antitumor
activity. Thus, comparisons of anticancer effects were conducted only between the daily
dexamethasone and prednisolone treatments. A decrease in PSA levels of ≥50% was detect‐
ed in 16 of 39 (41%) of the dexamethasone‐treated patients and in 8 of 36 (22%) predniso‐
lone‐treated patients. Although this difference did not approach statistical significance, the
investigators concluded that dexamethasone might be a more effective treatment than pre‐
dnisolone. Other investigators have supported this conclusion [70].
4.2. Combination with next‐generation antiandrogens
One clinical study evaluated the anticancer effects and safety profile of abiraterone acetate
when used in combination with prednisone as a means to suppress secondary mineralocorti‐
coid excess [71]. Another study reported a reduction in the PSA levels >50% in CRPC patients
treated with dexamethasone in addition to abiraterone acetate [71]. This report also demon‐
strated that the anticancer effects of combination therapy of abiraterone acetate and prednisone
were detected regardless of prior dexamethasone exposure [71]. Furthermore, the PSA
response rates, defined as a 50% or more reduction in PSA levels associated with dexametha‐
sone and prednisolone were reported to be 47% and 24% (P = 0.05), respectively, in CRPC
patients during a randomized Phase II trial [67]. Based on this, a hypothesis that a “steroid
switch” from prednisone to dexamethasone would be effective in the treatment of CRPC
patients with disease progression under abiraterone and prednisone treatment has been
suggested [72]. In fact, one retrospective study of 30 CRPC patients who underwent such a
“steroid switch” while abiraterone was administered, showed that durable PSA responses
occurred in up to 40% of the patients [72]. In this study, the dosage of prednisolone or
dexamethasone was 5 mg b.i.d and 0.5–1.0 mg daily.
4.3. Combination with immunotherapy
Sipuleucel‐T is the recognized leading immunotherapeutic cancer vaccine (dendritic cell
vaccine therapy). A variety of additional immunotherapeutic agents that can be used singly
or combination therapy is currently under development. In fact, based on results from clinical
trials, personalized peptide vaccination strategies that use multiple anticancer peptides has
been reported to be effective and safe in CRPC patients [73, 74]. Several reports have also
demonstrated that low‐dose dexamethasone is a useful partner for personalized peptide
vaccination in the treatment of CRPC. This is because dexamethasone does not suppress the
immune system. Dexamethasone also exerts its anticancer effects in a direct manner as well as
by reducing AR signaling [5, 75]. Recently, Phase II randomized controlled trials have
demonstrated that immunotherapy that comprised personalized peptide vaccination and low‐
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dose dexamethasone was well‐tolerated in chemotherapy‐naive CRPC patients and yielded a
better outcome when compared to the effects of dexamethasone alone [76]. In short, progres‐
sion‐free survival periods, as evaluated by serum PSA responses, with peptide vaccine +
dexamethasone (n = 37) and dexamethasone alone (n = 35) were 22.0 and 7.0 months (P = 0.076),
respectively. In addition, the median overall survival in patients treated with peptide vaccine
+ dexamethasone (73.9 months) was significantly longer (P = 0.00084) than those treated with
dexamethasone alone (34.9 month)
4.4. Modulatory approach for castration‐resistant prostate cancer
Dexamethasone is often used as a component of modular therapy approaches in the treat‐
ment of CRPC. The aim of the modulatory approach is to inhibit the malignant activities of
cancer and stroma cells through regulation of a variety of different pathological features in‐
cluding cancer‐related molecules, angiogenesis, inflammation, and altered immune respons‐
es.
The effect of a modular therapy consisting of capecitabine, pioglitazone (PPARα/γ receptor
agonist), refecoxib (or etoricoxib, a cyclooxygenase (COX)‐2 inhibitor), and dexamethasone on
36 patients with metastatic CRPC was analyzed [77]. One half of treated patients (n = 18)
showed a biochemical response defined as a ≥25% PSA decrease. Median periods of progres‐
sion‐free and overall survival were 4 and 14.4 months, respectively [77]. Results from a study
on a modulatory therapy comprising imatinib (a platelet derived growth factor receptor
(PDGFR) inhibitor), pioglitazone, etoricoxib, dexamethasone, and low‐dose treosulfan have
also been reported [78]. In that Phase II study, the anticancer effects and adverse events of the
modular therapy were assessed in 61 CRPC patients. A total of the 23 patients (37.7%) were
reported as PSA responders. Median progression‐free survival period was approximately 15
months. However, all the patients experienced one or more adverse events and 27 patients
(41.5%) had serious events. The most frequent adverse event was peripheral edema (56.9%).
Nausea (38.5%), fatigue (35.4%), and dyspnea (35.4%) were also common occurrences. One of
key characteristics of CRPC is its heterogeneity. Therefore, a variety of different approaches is
essential in controlling tumor growth and progression. Based on this, modulatory therapy
would appear to be a useful strategy. However, in general, this approach has been associated
with a relatively high frequency of adverse events. In this section, we emphasized the impor‐
tance of dexamethasone because of its anticancer effects as a GR agonist and its suppression
of a variety of adverse events.
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